💊 Ozempic Dusts Off Rockefeller’s Playbook
Plus: AI That Can Skip 500 Million Years of Evolution, Tesla’s Competitors Are in the Playpen, and More
This week’s market, investing, and business insights from insiders and experts outside the mainstream media:
Novo Nordisk is eager to give out JABs as if it were the new COVID vaccine.
Ex-Meta researchers skipped a process that takes nature 500 million years.
Tesla’s poised to dominate full autonomous driving (here’s why).
A significant milestone in space exploration was marked by…China.
And more. Let’s get to it!
Follow us on Instagram | Advertise to our 7K+ subscribers
Top Insights of the Week
1. 💊 Ozempic Dusts Off Rockefeller’s Playbook
Move the slider and melt away a few pounds. That was HP’s instant slim feature on cameras back in 2006. It tapped into fad diets and quick-fixes. Novel but not enough. Today, Ozempic is the real-life instant slim.
A quick fix that ignores the root cause. And the company behind it, Novo Nordisk, is eager to give out JABs as if it were the new COVID vaccine.
Novo Nordisk paid U.S. obesity doctors $25.8M to promote Ozempic.
Healthcare system is promoting Ozempic as a lifelong solution.
Medicare spending on GLP-1 drugs soared, $57M in 2018 to $5.7B in 2022.
Nothing new here. The medical industry prioritizes profit over root causes.
Abraham Flexner, an “educator” paid by Rockefeller, invented the pharmaceutical industry in 1909. That's right, not a doctor.
He saw profit in siloing conditions and treating them. Focusing on intervention over health.
2. 🧬 AI That Can Skip 500 Million Years of Evolution
Previously, we noted AlphaFold, Google's AI for predicting protein structures, as a potential moat. That has changed.
Recently, ex-Meta researchers managed to skip a process that takes nature 500 million years. They used an AI model, ESM3, to create a new protein variant.
What does this mean?
Similar to Google’s AlphaFold: potential for cancer drugs with minimal side effects, anti-aging treatments, and faster/cheaper drug discovery.
The company is called EvolutionaryScale and recently raised $142M from Amazon and Nvidia.
3. 😯 Probably the Most Important report on the US Stockmarket you will read This Year*
Topdown Charts.
Topdown Charts has just released a Major Report on the US Stockmarket covering long-term perspectives on price, fundamental trends, opportunities in sectors + styles, global stocks, and issues in asset allocation.
*Sponsored
4. 😬 Tesla’s Competitors Are in the Playpen
Full autonomous driving is a no brainer. It helps solve…
~5 million car accidents each year.
~2.3 million people have auto accident related injuries each year.
~40,000 people die in auto accidents each year.
DUI, speeding, and not using seat belts, responsible for ~80% of deaths.
Full autonomous driving still faces two major problems. Inference and learning. In other words, making sense of all the data and having data to start with. Tesla’s problem is inference. A good problem to have. While others stay in the playpen (controlled environments), Tesla has been collecting extensive real-world data from day one.
Equipped with cameras, ultrasonic sensors, and radar.
Strong connectivity for real-time data transmission to Tesla's servers.
FSD (Full Self-Driving) operates alongside the driver, comparing actions and logging discrepancies to improve.
That's why they're poised to dominate and plan to unveil a robotaxi without steering wheels or pedals this summer.
But don't count anyone out just yet.
Waymo is providing fully autonomous rides across the city, 24/7.
Baidu launched China's first 24/7 autonomous taxi service.
UBS estimated robotic car revenue at $2 trillion by 2030.
*Sponsored
Maritime Analytica
Your gateway to the world of container shipping🚢. Join over +11K subscribers in exploring the latest maritime news 📰, sustainability practices 🌱, cutting-edge tech 🌐, financial trends💸, captivating games 🎮, and inspiring maritime arts 🎨. Stay informed, stay ahead. ⚓ Join today for free.
Aimply Briefs
Cut through the noise with Aimply Briefs. We filter thousands of stories daily to deliver a 5-minute personalized news digest. Tailored just for you—every day. Subscribe for free.
AIModels.fyi
Get a digest of new AI research, how-to guides, and top models. Subscribe for free.
Top 3 Charts of the Week
1. 🚀 Lunar Exploration Is Popular Again
China landed lunar rock samples, marking a major space exploration milestone.
China's aiming for astronauts on the Moon by 2030 and a base by 2035.
Global space competition intensifies with 70+ countries and companies.
2. 🐟 We Farm More Fish Than We Catch
Over 50% of the world's seafood is now farmed, not wild-caught.
Aquaculture produced 94 million metric tons in 2022, vital as wild fish deplete.
Impacts global food supply, with Asia driving 90% of production.
3. ☢️ Uranium Prices Have Soared
China and India boost nuclear output, driving uranium prices up 233%.
Paladin acquires Fission Uranium for $833M, creating a leading nuclear fuel company and spurring new nuclear projects.
Increased nuclear investment impacts global energy markets.
Ready to get serious about investing?
Then join our growing list of premium subscribers who have already placed themselves on the path to greater wealth.
Subscribe today for just $9/month.
🚨 What you get when you become a premium subscriber 🚨
TOP 5 STOCK IDEAS, picked with sniper precision, delivered to your inbox every Monday morning, before the market opens.
HIGH CONVICTION TRADE ALERTS throughout the week as we spot them.
Access to OUR COMMUNITY of fellow traders, where you can ask questions & post comments.
END OF THE MONTH SUMMARY of which ideas performed best.
NO GUESSWORK. You'll get to see our entry point, stop loss, and profit target.
INSTANT ACCESS, no strings attached. No commitment. Cancel anytime.
UNCONVENTIONAL MARKET & MACRO INSIGHTS, discover opportunities and risks not highlighted elsewhere.
Enjoy this content? Subscribe to our Instagram
We take the responsibility of emailing you seriously. If you don't want to receive stock market updates and trading education anymore, you can unsubscribe at any time.
Nothing in this email is intended to serve as financial advice. Do your own research. See important disclaimer & terms of service.